NCT02867956View on ClinicalTrials.gov

Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 10, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

September 10, 2019

Conditions
Ovarian Cancer
Interventions
DRUG

Apatinib

Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.

DRUG

Etoposide

Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT02867956 - Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer | Biotech Hunter | Biotech Hunter